These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25854825)

  • 1. Effectiveness of long-acting injectable antipsychotics: a clinical perspective.
    Castillo EG; Stroup TS
    Evid Based Ment Health; 2015 May; 18(2):36-9. PubMed ID: 25854825
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delaying time to relapse in schizophrenia. The role of long-acting injectable antipsychotics.
    Muller R
    Manag Care; 2014 Apr; 23(4 Suppl 1):2-3. PubMed ID: 25029779
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
    Correll CU; Lauriello J
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.
    Heres S; Lambert M; Vauth R
    Eur Psychiatry; 2014 Nov; 29 Suppl 2():1409-13. PubMed ID: 25455704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting injectable antipsychotics in early psychosis: a literature review.
    Emsley R; Chiliza B; Asmal L; Mashile M; Fusar-Poli P
    Early Interv Psychiatry; 2013 Aug; 7(3):247-54. PubMed ID: 23342964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
    Haddad PM; Taylor M; Niaz OS
    Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical perspective on antipsychotic long-acting injections.
    Johnson DA
    Br J Psychiatry Suppl; 2009 Nov; 52():S7-12. PubMed ID: 19880921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting injectable antipsychotics treatment during COVID-19 pandemic - A new challenge.
    Ifteni P; Dima L; Teodorescu A
    Schizophr Res; 2020 Jun; 220():265-266. PubMed ID: 32349886
    [No Abstract]   [Full Text] [Related]  

  • 12. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic formulation and one-year rehospitalization of schizophrenia patients: a population-based cohort study.
    Huang SS; Lin CH; Loh el-W; Yang HY; Chan CH; Lan TH
    Psychiatr Serv; 2013 Dec; 64(12):1259-62. PubMed ID: 24292730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Financial impact of a pharmacist-managed clinic for long-acting injectable antipsychotics.
    Phan SV; VandenBerg AM
    Am J Health Syst Pharm; 2012 Jun; 69(12):1014-5. PubMed ID: 22644972
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].
    Azorin JM
    Encephale; 2013 Sep; 39 Suppl 2():S121-3. PubMed ID: 24084422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.